Write a review
Reviews: 0
Manufacturers: Tekhnomedservis
Active ingredients
- Not indicated. See instructions
Disease class
- Papillomaviruses as a cause of diseases classified elsewhere
- Tick-borne viral encephalitis
- Cytomegalovirus disease
- Disease caused by the human immunodeficiency virus [HIV], appearing as infectious and parasitic diseases
- Chronic viral hepatitis C
- Herpetic infection, unspecified
Clinical and pharmacological group
- Not indicated. See instructions
Pharmacological action
- Antiviral
- Immunomodulatory
Pharmacological group
- Antiviral (except HIV) drugs
- Other immunomodulators
Solution for intramuscular administration Ferrovir (Ferrovir)
Instructions for medical use of the drug
Description of pharmacological action
Activates antiviral, antifungal and antimicrobial immunity. Shows antiviral action against RNA and DNA viruses. Course use (for 14 days) in the treatment of AIDS/HIV infection increases the level of CD4+ lymphocytes in the blood. This increase continues for 1–1.5 months after the end of treatment. At the same time, the viral load in the body decreases, which is reflected in a decrease in the concentration of HIV RNA compared to the initial level. With recurrent herpes infection, the duration of relapse is reduced and long-term remission occurs after a 10-day course of treatment. In the complex treatment of patients with chronic hepatitis C, it helps to improve treatment tolerance (reduce dizziness, nausea, etc.), reduce the replicative activity of the HCV virus of all genotypes and transfer the process to the latent phase with restoration of liver cells and inhibition of viral replication. Active in the presence of viruses of the main and opportunistic diseases. There is evidence of positive therapy with Ferrovir® for diseases caused by the human papillomavirus and the Epstein-Barr virus.
Indications for use
- herpetic infection caused by herpes simplex virus types 1 and 2, incl. generalized in immunocompetent individuals; — CMV infection; — warts caused by the human papillomavirus, incl. high-risk types - 16, 18; - hepatitis C; — tick-borne encephalitis; — HIV infection, incl. in combination with hepatitis C or recurrent herpes infection, as well as other opportunistic viral infections.
Release form
doses for internal lingual administration 15 mg/ml; bottle (bottle) 5 ml, contour plastic packaging 5, cardboard pack 1; doses for internal lingual administration 15 mg/ml; bottle (bottle) 2 ml, contour plastic packaging 10, cardboard pack 1; doses for internal lingual administration 15 mg/ml; dark glass bottle (bottle) 2 ml, contour plastic packaging 5, cardboard pack 1; doses for internal lingual administration 15 mg/ml; dark glass bottle (bottle) 5 ml, contour plastic packaging 5, cardboard pack 1; doses for internal lingual administration 15 mg/ml; bottle (bottle) 5 ml, contour plastic packaging 5, cardboard pack 1; Warehouse Rozchin for internal lingual administration 15 mg / ml 1 ml sodium deoxyribonucleate complex with 0.015 g infusion, including: sodium deoxyribonucleate 0.0145-0.0165 g infusion 0.002-0.006 g additional substances: water for Injection in bottles according to 5 ml; There are 5 bottles in a cardboard package.
Pharmacodynamics
Activates antiviral, antifungal and antimicrobial immunity. It exhibits antiviral activity against RNA and DNA viruses. A course of treatment (lasting 14 days) during the treatment of SNID / HIV infection increases the level of CD4 + lymphocytes in the blood. This movement lasts for 1-1.5 months. after completing the course of treatment. At the same time, the viral presence in the body decreases, which is reflected in the reduced concentration of VIL RNA in the excretory stream. In case of recurrent herpetic infection, there is no relapse and remission occurs after a 10-day course of treatment. In complex treatment of patients for chronic hepatitis C, there is increased tolerance to treatment (reduced confusion, tediousness, etc.), reduced replication activity of the HCV virus of all genotypes and the transfer of the process into the latent phase. new liver cells and galvanization of viral replication. Active in the presence of viruses of the main and opportunistic illness. Data about positive therapy with Ferrovir® for illnesses caused by human papillonvirus and Epstein-Barr virus.
Pharmacokinetics
When administered intramuscularly, the liquid is absorbed and distributed in organs and tissues via endolymphatic transport; has a high affinity for organs of the hematopoietic system; take an active part in cellular metabolism, being formed in cellular structures. In the process of depleted exchange rate, the power can accumulate in organs and tissues. The duration of Cmax is 0.5 years (then the concentration of the drug in the blood begins to decrease, due to its distribution in organs and tissues). T1/2 - 36 year. With a large one-time administration (cutaneously for 24 years for 4 days), the accumulation of the drug in the spleen, lymph nodes and bone marrow is prevented (after the fifth administration, the concentration of the drug in all organs and tissues does not increase, after there is a decrease in performance). Excreted from the body in the form of metabolites, most importantly through the intestine and often through feces. The average time of absorption of the drug in organs and tissues is 72 years.
Use during pregnancy
Contraindicated for vaginosis. For an hour of rejoicing, follow the instructions for breastfeeding.
Contraindications for use
- hypersensitivity; - vagusness; - lactation; - child's age.
Side effects
There may be a short-term increase in body temperature (up to 38 ° C), redness and pain at the site of injection.
Directions for use and doses
V/m, we'll grow up. Herpetic infection - 5 ml (15 mg/ml) dose for intramuscular administration (75 mg per dose on dry water) 2 times per dose (150 mg) for 10 days. Based on the data of the remaining clinical studies, the effectiveness of the same course was demonstrated with a one-time dose of 5 ml (75 mg/dose) administered once per dose at an interval of 24 years, lasting 10 days. Papillomavirus infection - 5 ml (15 mg / ml) dose for intramuscular administration 1 time per dose at an interval of 72 years for 10 days. Cytomegalovirus infection - 5 ml (15 mg / ml) dose for intramuscular administration 2 times a day for 10 days. Hepatitis C - 5 ml (15 mg/ml) dose for intramuscular administration 2 times a day for 14 days. At the end of 14 days, the drug is administered in the same additional dose every other day. In / m, in length, with a length of 1-2 min. HIV infection or SNID - 5 ml (15 mg/ml) for intramuscular administration 2 times per dose (150 mg) for 14 days. If necessary, repeat the course of therapy after 1-1.5 months. Tick-borne encephalitis - 5 ml (15 mg/ml) dose for intramuscular administration 2 times a day for 5-10 days.
Overdose
No negative effects were identified.
Interactions with other drugs
The effect of anticoagulants is moderately potent. Complex therapy reduces the toxicity and negative effects of stagnant drugs (headache, fatigue, etc.).
Precautions for use
Intravenous administration of the drug is not allowed.
Special instructions for use
Dispense for injection immediately after opening the bottle. It is not allowed to save unopened vials.
Storage conditions
Protected in a bright place, at a temperature of 4-20 ° C.
Best before date
60 months
ATX classification:
J Antimicrobials for systemic use
J05 Antiviral drugs for systemic use
J05A Direct acting antivirals
J05AX Other antivirals
About the drug
Ferrovir
is an antiviral and immunomodulatory drug, which is a purified and standardized complex salt of sodium deoxyribonucleate with iron. Ferrovir has an antiviral and immunomodulatory effect, activates antiviral, antifungal and antibacterial immunity. Shows antiviral action against various RNA and DNA viruses. Clinical experience with the drug has shown its high activity and good tolerability.
Trade name of the drug:
Ferrovir
Chemical name:
Sodium deoxyribonucleate with iron complex.
Dosage form:
solution for intramuscular administration
Compound:
Active substance: 1 ml of solution contains 0.015 g of sodium deoxyribonucleate and 0.000048 g of iron oxide chloride. Excipient: water for injection
Description:
Transparent yellow liquid without foreign inclusions. Pharmacotherapeutic group: immunomodulatory and antiviral agent
ATX code:
JO5AX
Pharmacological properties
Pharmacodynamics:
Ferrovir is a biologically active substance - an extract from the milk of sturgeon or salmon fish (purified and standardized complex salt of sodium deoxyribonucleate with iron). The drug has antiviral and immunomodulatory effects, activates antiviral, antifungal and antimicrobial immunity. Shows antiviral action against various RNA and DNA viruses. Clinical experience with the drug has shown its high activity, good tolerability, lack of toxicity (IC50>4000 µg/ml), and undesirable side effects.
Indications for use:
Ferrovir is used in the treatment of patients with herpes, tick-borne encephalitis, hepatitis C. In combination therapy of HIV-infected patients and patients with AIDS, HIV-infected patients with hepatitis C, HIV-infected patients with recurrent herpes infection.
Contraindications:
Individual intolerance.
Pregnancy and lactation, childhood. Directions for use and dosage
:
- When treating herpes - 5 ml (15 mg/ml) solution for intramuscular administration 2 times a day for 10 days.
- When treating hepatitis C, Ferrovir is administered intramuscularly 2 times a day, 5 ml (15 mg/ml) solution for intramuscular administration for 14 days. Over the next 14 days, the drug is administered in the same daily dose every other day.
- For tick-borne encephalitis, the drug is administered 2 times a day, 5 ml (15 mg/ml) solution for intramuscular administration for 5 - 10 days.
- In the treatment of HIV infection or AIDS, the drug is prescribed intramuscularly for adults: 5 ml (15 mg/ml) solution for intramuscular administration (75 mg in terms of dry matter) 2 times a day (150 mg), for 14 days. If necessary, after 1-1.5 months, a second course of therapy is prescribed.
Side effects:
Possible short-term increase in body temperature (up to 38°C), hyperemia and moderate pain at the injection site.
Overdose:
No negative effects from overdose were identified.
Interaction with other drugs:
Moderately potentiates the effect of anticoagulants. In complex therapy, it reduces the toxicity and negative effects of the drugs used (headache, nausea, etc.)
Special instructions:
To reduce pain, Ferrovir is administered intramuscularly slowly over 1-2 minutes.
The solution for injection should be completely used immediately after opening the bottle; storing open bottles is not allowed. Intravenous administration of the drug is not allowed! Release form:
Solution for intramuscular administration 15 mg/ml in bottles of 2 ml, 5 ml of neutral or dark glass. Original packaging of 5 bottles of 5 ml or 10 bottles of 2 ml in a blister tray with instructions in a cardboard box.
Storage conditions:
In a place protected from light at a temperature from +4°С to +20?С. Keep out of the reach of children. Shelf life: 5 years. Do not use the drug after the expiration date indicated on the package.
Conditions for dispensing from pharmacies:
Dispensed with a doctor's prescription.
Official website: www.ferrovir.ru
The information on this site is intended for healthcare professionals only. The information presented is not intended to be used as medical advice. Responsibility for the care provided to a patient rests entirely with the health care professional based on his or her professional licensure, experience, and knowledge of the individual patient.
Similar drugs:
- Groprinosin Oral tablets
- Choludexan Capsule
- Lactobacterin siccum dry (Lactobacterin siccum) Lyophilisate for the preparation of solution for oral administration
- Wobenzym Oral tablets
- Anaferon for children (Anaferon filios) Lozenges
- Ursosan Capsule
- Bifidumbacterin Capsule
- Immunoflazidum (IMMUNOFLAZIDUM) Syrup
- Isoprinosine Oral tablets
- Derinat Solution for injection
** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use Ferrovir, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.
Are you interested in the drug Ferrovir? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.
** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Ferrovir is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!
If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.
